BioPharma Resources

Drug Trial Radar · NCT04643002

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

258

Planned (sponsor's estimate)

Start

Jan 25, 2021

Primary completion

Sep 13, 2027

Study completion Apr 20, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

Conditions

  • Plasma Cell Myeloma Refractory

Interventions

  • IsatuximabDrug

    Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

  • DexamethasoneDrug

    Pharmaceutical form: Tablet; Route of administration: Oral

  • PomalidomideDrug

    Pharmaceutical form: Capsule; Route of administration: Oral

  • Belantamab mafodotinDrug

    Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

  • PegenzileukinDrug

    Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

  • SAR439459Drug

    Pharmaceutical form: Solution for injection; Route of administration: Intravenous

  • BelumosudilDrug

    Pharmaceutical form: tablet; route of administration: oral

  • EvorpaceptDrug

    Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximabTime frame: Through the end of cycle 1 (approximately 6 weeks)
  2. Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)Time frame: Up to approximately 28 months after the First patient in or scheduled assessment
  3. Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudiesTime frame: Up to approximately 28 months after the First patient in or scheduled assessment

Locations

28 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham- Site Number : 8400001

    Birmingham, Alabama · Completed

  • Winship Cancer Institute of Emory University- Site Number : 8400010

    Atlanta, Georgia · Recruiting

  • University of Illinois-Chicago - College of Medicine- Site Number : 8400007

    Chicago, Illinois · Completed

  • University of Michigan Health System - Ann Arbor- Site Number : 8400004

    Ann Arbor, Michigan · Recruiting

  • Roswell Park Cancer Institute- Site Number : 8400008

    Buffalo, New York · Recruiting

  • The Ohio State University- Site Number : 8400012

    Columbus, Ohio · Recruiting

  • Investigational Site Number : 0360006

    Wollongong, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360003

    Heidelberg, Victoria, Australia · Completed

  • Investigational Site Number : 0360002

    Melbourne, Victoria, Australia · Recruiting

  • Investigational Site Number : 0360001

    Richmond, Victoria, Australia · Recruiting

  • Investigational Site Number : 2500002

    Lille, France · Recruiting

  • Investigational Site Number : 2500001

    Nantes, France · Recruiting

  • Investigational Site Number : 2500003

    Paris, France · Recruiting

  • Investigational Site Number : 2500004

    Paris, France · Recruiting

  • Investigational Site Number : 2760006

    Frankfurt, Germany · Recruiting

  • Investigational Site Number : 2760008

    Lübeck, Germany · Recruiting

  • Investigational Site Number : 3000002

    Athens, Greece · Recruiting

  • Investigational Site Number : 3000001

    Athens, Greece · Recruiting

  • Investigational Site Number : 3760002

    Jerusalem, Israel · Recruiting

  • Investigational Site Number : 3760003

    Ramat Gan, Israel · Recruiting

  • Investigational Site Number : 3760001

    Tel Aviv, Israel · Recruiting

  • Investigational Site Number : 3800001

    Meldola, Reggio Emilia, Italy · Recruiting

  • Investigational Site Number : 5780001

    Oslo, Norway · Recruiting

  • Puerto Rico Medical Research Center- Site Number : 8400005

    Hato Rey, Puerto Rico, Puerto Rico · Completed

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, South Korea · Recruiting

  • Investigational Site Number : 4100004

    Seoul, Seoul-teukbyeolsi, South Korea · Recruiting

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, South Korea · Recruiting

  • Investigational Site Number : 4100003

    Seoul, Seoul-teukbyeolsi, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.